Welcome to our dedicated page for Merus N.V. Common Shares news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V. Common Shares stock.
Merus N.V. (Nasdaq: MRUS) is a clinical-stage immuno-oncology company focused on creating innovative therapies to treat and potentially cure cancer. At the heart of Merus' approach is its proprietary Biclonics® and Triclonics® technology platforms, which generate full-length human bispecific and trispecific antibodies. These advanced therapeutics are designed to engage the immune system to kill tumor cells and inhibit tumor cell growth pathways simultaneously.
Core Business
Merus' core business revolves around the discovery and development of bispecific antibody therapeutics. Their flagship technology, Biclonics®, can attack tumors in multiple ways, making them highly effective against various cancer types. The company’s portfolio includes several promising candidates, such as MCLA-128, which targets HER2 and HER3 receptors in gastric and breast cancers; MCLA-117, targeting AML; MCLA-158 (petosemtamab), focused on head and neck squamous cell carcinoma; and MCLA-145, developed for solid tumors.
Latest Achievements and News
As of May 2024, Merus has received the FDA's Breakthrough Therapy Designation (BTD) for petosemtamab in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after treatment with platinum-based chemotherapy and PD-1/PD-L1 antibodies. This significant milestone is based on the promising data from the ongoing phase 1/2 trial of petosemtamab as a monotherapy, showing substantial improvement in clinically significant endpoints. Furthermore, Merus has announced plans to initiate a phase 3 trial in mid-2024 to evaluate the combination of petosemtamab and pembrolizumab in previously untreated patients.
Additionally, Merus revealed the acceptance of abstracts for MCLA-145 and MCLA-129 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations highlighted the clinical activity of MCLA-145 in advanced solid tumors and the efficacy of MCLA-129 in non-small cell lung cancer (NSCLC).
Financial Condition and Partnerships
Merus has a solid financial foundation, bolstered by strategic partnerships and collaborations. Notably, Merus collaborates with Betta Pharmaceuticals to develop MCLA-129 in China while retaining global rights outside China. The company’s financial strategy includes advancing its clinical development programs and supporting preclinical research and technology development through successful capital raises.
About Merus N.V.
Merus N.V. is dedicated to the development of multispecific antibody therapeutics, referred to as Multiclonics®. These therapeutics have been observed in preclinical and clinical studies to exhibit the same features as conventional human monoclonal antibodies, including long half-life and low immunogenicity. For more information, visit Merus’ official website, Twitter, and LinkedIn.
Merus N.V. (Nasdaq: MRUS) announced that its CEO, Bill Lundberg, will present at the H.C. Wainwright Global Investment Conference. This presentation will occur on May 24, 2022, with a live webcast available at 7:00 a.m. ET on the company's Investors page. An archived version will be accessible for a limited time following the event.
Merus focuses on developing innovative full-length multispecific antibodies, including its proprietary Biclonics® and Triclonics® therapies, which have demonstrated promising features in clinical studies.
Merus N.V. (Nasdaq: MRUS) reported its Q1 2022 financial results, indicating a total revenue increase to $11.7 million from $8.4 million in Q1 2021, driven by collaboration revenue growth. The company ended Q1 with cash reserves of $384.3 million, down from $430.8 million at year-end 2021. Net loss for the quarter was $18.9 million, slightly improving from a loss of $10.2 million year-over-year. Merus is excited about its upcoming ASCO presentation on Zenocutuzumab, highlighting its ongoing clinical trials and pipeline growth. Cash runway is expected to last beyond 2024.
Merus N.V. (Nasdaq: MRUS) announced that an abstract showcasing interim clinical data for zenocutuzumab (Zeno), a bispecific antibody targeting NRG1+ cancer, has been selected for oral presentation at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The presentation, titled 'Efficacy and safety of zenocutuzumab,' will take place on June 5. Merus is currently conducting the phase 1/2 eNRGy trial and will discuss updated interim data during a conference call on the same day.
Merus N.V. (Nasdaq: MRUS) announced the publication of a preclinical report on its bispecific antibody, petosemtamab (Peto, MCLA-158), in Nature Cancer. The report highlights Peto's potent growth inhibition of colorectal cancer organoids and its unique mechanism that triggers EGFR degradation in LGR5-expressing organoids. Peto shows promising results compared to cetuximab, with superior growth inhibition in KRAS mutant CRC models. The company is currently enrolling patients for a Phase 1 trial and plans a clinical update in the second half of 2022.
Merus N.V. (MRUS) announced promising preclinical data for MCLA-129, highlighting its ability to promote Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) in non-small cell lung cancer (NSCLC). The findings, which show MCLA-129's significant inhibition of growth in a patient-derived EGFR exon20 insertion tumor model, will be presented at the AACR Annual Meeting 2022. Currently, MCLA-129 is in a phase 1/2 clinical trial, with updates anticipated in the second half of 2022.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that its CEO, Bill Lundberg, M.D., will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13 from 10:15-10:55 a.m. ET. The event will be accessible via a live webcast on the Company's investor page, with an archived version available afterward. Merus specializes in developing innovative multispecific antibodies, including its unique Biclonics® and Triclonics®, which show promise in clinical studies.
Rallybio Corporation announces significant changes to its Board of Directors. Christine Nash and Hui Liu have been appointed as new members, bringing extensive experience in rare diseases and business development, respectively. Tim Shannon, M.D. will resign from the Board, effective at the 2022 Annual Meeting of Shareholders. The company aims to leverage the expertise of new board members to advance its product portfolio for rare diseases.
Merus N.V. (MRUS) has announced the upcoming presentation of a poster discussing the mechanism and effectiveness of its drug MCLA-129 at the AACR Annual Meeting 2022 on April 10. MCLA-129 targets EGFR and c-MET, critical in treating non-small cell lung cancer (NSCLC). Currently, MCLA-129 is in a phase 1/2 clinical trial aimed at assessing safety, tolerability, and clinical activity in patients with advanced tumors. Merus has a collaboration with Betta Pharmaceuticals for its development in China while retaining global rights outside the region.
Merus N.V. (Nasdaq: MRUS) reported financial results for 2021, revealing a net loss of $66.8 million.
Collaboration revenue increased to $49.1 million, up from $29.9 million in 2020, driven by substantial contributions from Lilly and Incyte. Research and development expenses rose to $98.2 million, reflecting higher costs related to zenocutuzumab (Zeno) and MCLA-129. The company ended the year with cash, cash equivalents, and marketable securities of $430.7 million, projected to sustain operations beyond 2024. Clinical updates for Zeno, petosemtamab, and MCLA-129 are expected in 2022.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in several upcoming investor conferences. These include the Guggenheim Healthcare Talks/2022 Oncology Conference on February 10, the Citi 2022 Virtual Immuno-Oncology Summit on February 16, and the 11th Annual SVB Leerink Global Healthcare Conference on February 17. Webcasts of these events will be available on the Company's Investors page, with archived presentations accessible for a limited time.
FAQ
What is the current stock price of Merus N.V. Common Shares (MRUS)?
What is the market cap of Merus N.V. Common Shares (MRUS)?
What is the core business of Merus N.V.?
What are some of Merus' key product candidates?
What significant recent achievement has Merus reported?
What are Biclonics®?
What is the status of MCLA-145 and MCLA-129?
What are Multiclonics®?
Who are Merus' key partners?
What are the financial strategies of Merus?
What is the purpose of the latest capital raise by Merus?
Where can I find more information about Merus N.V.?
